🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06137196
Recruiting Observational

Risk Identification Factors for Pulmonary Function Impairment in AIDS Patients Recovered From Severe Pneumonia

NCT06137196 · tracked via the Priya Life Science China tracker
Sponsor
Guangzhou 8th People's Hospital
Phase
Observational
Started
2023-11-01
Last updated
2023-11-18

Condition(s) studied

AIDSPneumonia

Study summary

Screening for risk factors related to lung function impairment in patients who have recovered from AIDS with severe pneumonia, to provide clinical evidence for early identification and intervention of lung function damage in this population.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: 1. Confirmed HIV infection; 2. Progression to the AIDS stage: CD4+ count \<200 cells/µL and/or occurrence of opportunistic infections associated with AIDS; 3. Age between 18 to 65 years; 4. Meet the diagnostic criteria for severe pneumonia, with reference to the 2021 treatment guidelines for community-acquired pneumonia developed by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA). Exclusion Criteria: 1. Concurrent central nervous system lesions, severe liver disease, or cirrhosis; 2. Concurrent AIDS-related or non-related tumors; 3. Women who are pregnant or breastfeeding; 4. Presence of serious underlying diseases such as heart, lung, liver, kidney, etc.; 5. Alcohol abuse or drug use; 6. The researcher believes that the overall condition of the subject affects the evaluation and completion of the trial

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Guangzhou Eighth People's Hospital, Guangzhou Medical University Guangzhou Guangdong Recruiting

More Guangzhou 8th People's Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06137196 on ClinicalTrials.gov ↗ ← All trials in China